Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1472012 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $23.08Day −0.13%Mkt cap $2.6B1Y +114.7%Off 52W high −16.5%Vol (1Y) 69.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,361 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest15.2% of sh out |
| Days to cover10.5d |
| 13F net flow (QoQ)+5.93% |
| Top-10 13F concentration63.5% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$4.0M |
| Earnings (TTM)-$224.6M |
| ROE−52.1% |
| Net margin−3060.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+7.4% |
| 1Y+114.7% |
| 3Y+222.3% |
| 5Y+42.3% |
| Since incept. (ann.)−5.4% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)69.8% |
| Ann. volatility (3Y)73.7% |
| Sharpe (1Y)1.48 |
| Sharpe (3Y)0.89 |
| Max drawdown (1Y)−33.6% |
| Max drawdown (3Y)−79.7% |
| Beta (3Y vs SPY)1.45 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 17.0M | $371M | 15.00% | +2.5% |
| T. Rowe Price Investment Management, Inc. | 16.4M | $358M | 14.46% | +11.8% |
| BlackRock, Inc. | 8.2M | $179M | 7.22% | +7.6% |
| Redmile Group, LLC | 5.6M | $122M | 4.91% | −2.8% |
| STATE STREET CORP | 5.4M | $118M | 4.77% | +39.6% |
| PRIMECAP MANAGEMENT CO/CA/ | 4.8M | $105M | 4.23% | +2.2% |
| WELLINGTON MANAGEMENT GROUP LLP | 4.7M | $103M | 4.18% | +406.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4M | $97M | 3.92% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 103.1% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 18,658,002 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.48 | — | $0 | −100.0% |
| 2025-12-31 | 2026-03-03 | — | — | $0 | −100.0% |
| 2025-09-30 | 2025-11-06 | −$0.65 | — | $0 | −100.0% |
| 2025-06-30 | 2025-08-06 | −$0.50 | — | $4.0M | +69.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
